- $3.27bn
- $2.44bn
- $218.71m
Brief: Ideaya Biosciences Announces Successful FDA Type D Meeting for Darovasertib
Brief: Ideaya Biosciences Announces Phase 1/2 Expansion For Ide397 And Trodelvy® Combination In Mtap-Deletion Urothelial Cancer
U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple
Ideaya falls as analysts cautious despite eye cancer drug receiving FDA's 'breakthrough' tag
Brief: IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation For Darovasertib Monotherapy In Neoadjuvant Uveal Melanoma
Brief: IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor
Ideaya Biosciences Inc Reports Results For The Quarter Ended December 31: Earnings Summary
U.S. RESEARCH ROUNDUP-Boeing, Philip Morris, Walmart
U.S. STOCKS ON THE MOVE-Tesla, Hyatt Hotels, General Dynamics
Ideaya Biosciences falls as quarterly loss widens
Brief: Hengrui Pharmaceuticals Signs SHR-4849 Project License Agreement With Ideaya Biosciences
Brief: Ideaya Announces Idmc Recommendation Of Move-Forward Dose In Part 2A Of Registration-Enabling Trial Of Darovasertib And Crizotinib Combination
Brief: Ideaya Announces Development Candidate Nomination Of Ide251
Brief: IDEAYA Biosciences Announces Development Candidate Nomination Of IDE892
U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix
Brief: IDEAYA Biosciences Appoints Stu Dorman As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-BXP, Hubspot, Qualcomm
Brief: Ideaya Biosciences Announces Ind-Clearance For Werner Helicase Development Candidate Ide275 (Gsk959) For A Phase 1 Study In Msi-High Solid Tumors